文献速递产科母胎医学

妊娠19至25周普遍常规超声宫颈长度测量的成本效益

Cost-effectiveness of universal routine sonographic cervical-length measurement at 19 to 25 weeks' gestation.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-02-21

该研究基于以色列卫生部国家分娩登记数据构建决策模型,比较普遍宫颈长度筛查(对宫颈长度<25 mm者给予阴道黄体酮并每两周超声监测)与不筛查策略的成本效益。作者结论认为应将普遍宫颈长度筛查纳入中孕期常规畸形筛查。

要点

  • 增量成本效益比为-2676美元/质量调整生命年,每避免一例低出生体重或极低出生体重儿为-14718美元。
  • 在早产发生率<3%时,普遍筛查不带来成本节约。

核心结论

  • 作者认为应将国家普遍宫颈长度筛查纳入中孕期常规畸形筛查,因其可降低单胎妊娠早产和低出生体重儿发生率,节省新生儿相关成本并获得质量调整生命年。

研究设计与样本

  • 构建决策模型比较普遍宫颈长度筛查与不筛查两种策略,使用以色列卫生部国家分娩登记数据。
  • 所有中孕期宫颈长度<25 mm的妇女接受阴道黄体酮治疗并每两周超声监测宫颈动态及早产威胁。
  • 早产发生率、黄体酮疗效及宫颈长度测量准确性来自既往研究;成本数据来自以色列卫生部和以色列社会保障公开登记数据。
  • 实施蒙特卡洛模拟决策树模型、龙卷风图及一维和二维敏感性分析,计算基础病例及影响成本效益参数的敏感性。

主要发现

  • 不筛查策略的贴现质量调整生命年为30.179,普遍筛查为30.198,差值为0.018质量调整生命年。
  • 不筛查策略平均成本为1047美元,普遍筛查降低至998美元。
  • 增量成本效益比为-2676美元/质量调整生命年。
  • 蒙特卡洛模拟17万单胎新生儿显示,筛查组95.17%的婴儿在≥37周分娩,不筛查组为94.46%。

关键数值与推荐

  • 影响增量成本效益比的主要参数为早产发生率、宫颈长度测量的特异性和黄体酮治疗疗效。
  • 在早产发生率<3%时,普遍筛查不带来成本节约。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National second-trimester scanning of cervical length was introduced in Israel in 2010, and in the decade thereafter, a significant systematic reduction in preterm birth and in the delivery of low birthweight babies was found among singletons. OBJECTIVE: In this study, we sought to estimate the cost-effectiveness of a national policy mandating second-trimester cervical length screening by ultrasound, followed by vaginal progesterone treatment for short cervical length in comparison with no screening strategy. STUDY DESIGN: We constructed a decision model comparing 2 strategies, namely (1) universal cervical length screening, and (2) no screening strategy. This study used the national delivery registry of Israel's Ministry of Health. All women diagnosed with a second-trimester cervical length <25 mm were treated with vaginal progesterone and were monitored with a bimonthly ultrasound scan for cervical dynamics and threat of early delivery. Preterm birth prevalence associated with short cervical length, the efficacy of progesterone in preterm birth prevention, and the accuracy of cervical length measurements were derived from previous studies. The cost of progesterone and bimonthly sonographic surveillance, low birthweight delivery, newborn admission to intensive care units, the first-year costs of managing preterm birth and low birthweight, and instances of handicaps and the cost of their follow-up were extracted from the publicly posted registry of Israel's Ministry of Health and Israel Social Securities data. Monte Carlo simulations decision tree mode, Tornado diagrams, and 1- and 2-way sensitivity analyses were implemented and the base case and sensitivity to parameters that were predicted to influence cost-effectiveness were calculated. RESULTS: Without cervical length screening, the discounted quality-adjusted life years were 30.179, and with universal cervical length screening, it increased to 30.198 (difference of 0.018 quality-adjusted life years). The average cost of no screening for cervical length strategy was $1047, and for universal cervical length screening, it was reduced to $998. The calculated incremental cost-effectiveness ratio was -$2676 per quality-adjusted life year (dividing the difference in costs by the difference in quality-adjusted life years). Monte Carlo simulation of cervical length screening of 170,000 singleton newborns (rounded large number close to the number of singleton newborns in Israel) showed that 95.17% of all babies were delivered at gestational week ≥37 in comparison with 94.46% of babies with the no screening strategy. Given 170,000 singleton births, the national savings of screening for short cervical length when compared with no cervical length screening amounted to $8.31M annually, equating to $48.84 for a base case, and the incremental cost-effectiveness ratio for each case of low birthweight or very low birthweight avoided was -$14,718. A cervical length <25 mm was measured for 30,090 women, and of those, 24,650 were false positives. The major parameters that affected the incremental cost-effectiveness ratio were the incidence of preterm birth, the specificity of cervical length measurements, and the efficacy of progesterone treatment. At a preterm birth incidence of <3%, universal screening does not lead to a cost saving. CONCLUSION: National universal cervical length screening should be incorporated into the routine anomaly scan in the second trimester, because it leads to a drop in the incidence of preterm birth and low birthweight babies in singleton pregnancies, thereby saving costs related to the newborn and gaining quality-adjusted life years.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Leshno M, Meiri H, Maymon R, et al. Cost-effectiveness of universal routine sonographic cervical-length measurement at 19 to 25 weeks' gestation. Am J Obstet Gynecol MFM. 2024. PMID: 38387505. doi:10.1016/j.ajogmf.2024.101313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。